Day One Biopharmaceuticals Inc (NASDAQ: DAWN) on Friday, soared 8.23% from the previous trading day, before settling in for the closing price of $8.99. Within the past 52 weeks, DAWN’s price has moved between $5.64 and $16.76.
Annual sales at Healthcare sector company slipped by -38.09% over the past five years. The company achieved an average annual earnings per share of -0.76%. With a float of $74.54 million, this company’s outstanding shares have now reached $102.68 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Day One Biopharmaceuticals Inc is 27.40%, while institutional ownership is 75.18%. The most recent insider transaction that took place on Aug 18 ’25, was worth 27,786. In this transaction COO and CFO of this company sold 4,106 shares at a rate of $6.77, taking the stock ownership to the 278,000 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Gen Counsel & Secretary sold 4,365 for $6.77, making the entire transaction worth $29,538. This insider now owns 54,858 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.63 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.35) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Day One Biopharmaceuticals Inc (DAWN) is currently performing well based on its current performance indicators. A quick ratio of 8.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) saw its 5-day average volume 4.79 million, a positive change from its year-to-date volume of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 76.99%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 93.81%, which indicates a significant increase from 91.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was higher than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.38, while its 200-day Moving Average is $7.77. Nevertheless, the first resistance level for the watch stands at $10.14 in the near term. At $10.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.11. If the price goes on to break the first support level at $9.17, it is likely to go to the next support level at $8.60. Assuming the price breaks the second support level, the third support level stands at $8.20.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
Market capitalization of the company is 999.03 million based on 102,676K outstanding shares. Right now, sales total 131,160 K and income totals -95,500 K. The company made 33,910 K in profit during its latest quarter, and -30,320 K in sales during its previous quarter.
